Capsule Influences the Deposition of Critical Complement C3 Levels Required for the Killing of Burkholderia pseudomallei via NADPH-Oxidase Induction by Human Neutrophils

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Woodman, Michael E ^a   Worth, Randall G ^a   Wooten, R Mark ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTICLE; BACTERIAL CLEARANCE; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS; COMPLEMENT DEPOSITION; CONTROLLED STUDY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUTROPHIL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; RESPIRATORY BURST;

BACTERIAL CAPSULES; BURKHOLDERIA PSEUDOMALLEI; COMPLEMENT C3; HUMANS; MELIOIDOSIS; NADPH OXIDASE; NEUTROPHILS; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; RESPIRATORY BURST; VIRULENCE;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS;

EID: 84871341238     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052276     Document Type: Article

References (100)

1. Chaowagul W, White NJ, Dance DA, Wattanagoon Y, Naigowit P, et al. (1989) Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 159: 890-899.
2. Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, et al. (2000) Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 31: 981-986.
3. Currie BJ, Fisher DA, Howard DM, Burrow JN, Selvanayagam S, et al. (2000) The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop 74: 121-127.
4. White NJ, (2003) Melioidosis. Lancet 361: 1715-1722.
5. Leelarasamee A, (2000) Melioidosis in Southeast Asia. Acta Trop 74: 129-132.
6. Cheng AC, Currie BJ, (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383-416.
7. Corral DM, Coates AL, Yau YC, Tellier R, Glass M, et al. (2008) Burkholderia pseudomallei infection in a cystic fibrosis patient from the Caribbean: a case report. Can Respir J 15: 237-239.
8. Pérez JM, Petiot A, Adjidé C, Gerry F, Goursaud R, et al. (1997) First case report of melioidosis in Guadeloupe, a French West Indies archipelago. Clin Infect Dis 25: 164-165.
9. Rolim DB, Vilar DC, Sousa AQ, Miralles IS, de Oliveira DC, et al. (2005) Melioidosis, northeastern Brazil. Emerg Infect Dis 11: 1458-1460.
10. Dorman SE, Gill VJ, Gallin JI, Holland SM, (1998) Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin Infect Dis 26: 889-894.
11. Inglis TJ, Rolim DB, Q SA, (2006) Melioidosis in the Americas. Am J Trop Med Hyg 75: 947-954.
12. Miralles IS, Maciel Mdo C, Angelo MR, Gondini MM, Frota LH, et al. (2004) Burkholderia pseudomallei: a case report of a human infection in Ceará, Brazil. Rev Inst Med Trop Sao Paulo 46: 51-54.
13. Christenson B, Fuxench Z, Morales JA, Suarez-Villamil RA, Souchet LM, (2003) Severe community-acquired pneumonia and sepsis caused by Burkholderia pseudomallei associated with flooding in Puerto Rico. Bol Asoc Med P R 95: 17-20.
14. Dance DA, (2000) Melioidosis as an emerging global problem. Acta Trop 74: 115-119.
15. Currie BJ, Dance DA, Cheng AC, (2008) The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg 102: 1-4.
16. Currie BJ, Ward L, Cheng AC, (2010) The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4: e900.
17. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, Lertpatanasuwun N, Intaranongpai S, et al. (1999) Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 29: 408-413.
18. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G, (2005) Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 43: 970-972.
19. Jeddeloh JA, Fritz DL, Waag DM, Hartings JM, Andrews GP, (2003) Biodefense-driven murine model of pneumonic melioidosis. Infect Immun 71: 584-587.
20. Vietri NJ, DeShazer D (2007) Melioidosis. Medical Aspects of Biological Warfare. Washington, DC.: Borden Institute, Walter Reed Army Medical Center. 147-166.
21. Titball RW, Russell P, Cuccui J, Easton A, Haque A, et al. (2008) Burkholderia pseudomallei: animal models of infection. Trans R Soc Trop Med Hyg 102.
22. FESAP (2011) Recommendations concerning the select agent program.
23. Pilatz S, Breitbach K, Hein N, Fehlhaber B, Schulze J, et al. (2006) Identification of Burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Infect Immun 74: 3576-3586.
24. Stevens MP, Haque A, Atkins T, Hill J, Wood MW, et al. (2004) Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 150: 2669-2676.
25. Stevens MP, Stevens JM, Jeng RL, Taylor LA, Wood MW, et al. (2005) Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei. Mol Microbiol 56: 40-53.
26. Stevens MP, Wood MW, Taylor LA, Monaghan P, Hawes P,et al. (2002) An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 46: 649-659.
27. Warawa J, Woods DE, (2005) Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol Lett 242: 101-108.
28. Kespichayawattana W, Rattanachetkul S, Wanun T, Utaisincharoen P, Sirisinha S, (2000) Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect Immun 68: 5377-5384.
29. Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, et al. (2011) The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun 79: 1512-1525.
30. Reckseidler-Zenteno SL, DeVinney R, Woods DE, (2005) The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun 73: 1106-1115.
31. Warawa JM, Long D, Rosenke R, Gardner D, Gherardini FC, (2009) Role for the Burkholderia pseudomallei capsular polysaccharide encoded by the wcb operon in acute disseminated melioidosis. Infect Immun 77: 5252-5261.
32. Reckseidler SL, DeShazer D, Sokol PA, Woods DE, (2001) Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 69: 34-44.
33. Brett PJ, Deshazer D, Woods DE, (1997) Characterization of Burkholderia pseudomallei and Burkholderia pseudomallei-like strains. Epidemiol Infect 118: 137-148.
34. Brett PJ, DeShazer D, Woods DE, (1998) Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48: 317-320.
35. Smith MD, Angus BJ, Wuthiekanun V, White NJ, (1997) Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun 65: 4319-4321.
36. Charoensap J, Utaisincharoen P, Engering A, Sirisinha S, (2009) Differential intracellular fate of Burkholderia pseudomallei 844 and Burkholderia thailandensis UE5 in human monocyte-derived dendritic cells and macrophages. BMC Immunol 10: 20.
37. Kespichayawattana W, Intachote P, Utaisincharoen P, Sirisinha S, (2004) Virulent Burkholderia pseudomallei is more efficient than avirulent Burkholderia thailandensis in invasion of and adherence to cultured human epithelial cells. Microb Pathog 36: 287-292.
38. French CT, Toesca IJ, Wu TH, Teslaa T, Beaty SM, et al. (2011) Dissection of the Burkholderia intracellular life cycle using a photothermal nanoblade. Proc Natl Acad Sci USA 108: 12095-12100.
39. Brett PJ, Woods DE, (2000) Pathogenesis of and immunity to melioidosis. Acta Trop 74: 201-210.
40. Lazar Adler NR, Govan B, Cullinane M, Harper M, Adler B, et al. (2009) The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease? FEMS Microbiol Rev 33: 1079-1099.
41. Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ, (2007) A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 195: 99-107.
42. Laws TR, Smither SJ, Lukaszewski RA, Atkins HS, (2011) Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis. Microb Pathog 51: 471-475.
43. Breitbach K, Klocke S, Tschernig T, van Rooijen N, Baumann U, et al. (2006) Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice. Infect Immun 74: 6300-6309.
44. Alba-Loureiro TC, Munhoz CD, Martins JO, Cerchiaro GA, Scavone C, et al. (2007) Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 40: 1037-1044.
45. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G, (2009) Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 77: 456-463.
46. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, et al. (1997) Impaired leucocyte functions in diabetic patients. Diabet Med 14: 29-34.
47. Naghibi M, Smith RP, Baltch AL, Gates SA, Wu DH, et al. (1987) The effect of diabetes mellitus on chemotactic and bactericidal activity of human polymorphonuclear leukocytes. Diabetes Res Clin Pract 4: 27-35.
48. Healey T, Selva-Nayagam S, (2001) Retrospective review of febrile neutropenia in the Royal Darwin Hospital, 1994-99. Intern Med J 31: 406-412.
49. Mukhopadhyay C, Chawla K, Vandana KE, Krishna S, Saravu K, (2010) Pulmonary melioidosis in febrile neutropenia: the rare and deadly duet. Trop Doct 40: 165-166.
50. Powell K, Ulett G, Hirst R, Norton R, (2003) G-CSF immunotherapy for treatment of acute disseminated murine melioidosis. FEMS Microbiol Lett 224: 315-318.
51. Cheng AC, Dasari P, Currie BJ, (2004) Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis. Eur J Clin Microbiol Infect Dis 23: 205-207.
52. Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Wuthiekanun V, et al. (2007) A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 45: 308-314.
53. Cheng AC, Stephens DP, Anstey NM, Currie BJ, (2004) Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 38: 32-37.
54. Stephens DP, Fisher DA, Currie BJ, (2002) An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 32: 143-148.
55. Egan AM, Gordon DL, (1996) Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect Immun 64: 4952-4959.
56. Razak N, Ismail G, (1982) Interaction of human polymorphonuclear leukocytes with Pseudomonas pseudomallei. J Gen Appl Microbiol 28: 509-518.
57. Jones AL, Beveridge TJ, Woods DE, (1996) Intracellular survival of Burkholderia pseudomallei. Infect Immun 64: 782-790.
58. DeShazer D, Brett PJ, Carlyon R, Woods DE, (1997) Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J Bacteriol 179: 2116-2125.
59. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods D, (1999) E (1999) Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 43: 465-470.
60. Heiss C, Burtnick MN, Wang Z, Azadi P, Brett PJ, (2012) Structural analysis of capsular polysaccharides expressed by Burkholderia mallei and Burkholderia pseudomallei. Carbohydr Res 15: 90-94.
61. Nauseef W (2007) Isolation of human neutrophils from venous blood. In: Quinn MT, DeLeo FR, Bokoch GM, editors. Methods in Molecular Biology. Totowa, NJ: Human Press Inc. 15-20.
62. Drevets DA, Canono BP, Leenen PJ, Campbell PA, (1994) Gentamicin kills intracellular Listeria monocytogenes. Infect Immun 62: 2222-2228.
63. van den Broek PJ, (1989) Antimicrobial drugs, microorganisms, and phagocytes. Rev Infect Dis 11: 213-245.
64. Mandell GL, (2005) Uptake, transport, delivery, and intracellular activity of antimicrobial agents. Pharmacotherapy 25: 130-133.
65. Prokesch RC, Hand WL, (1982) Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 21: 373-380.
66. DeShazer D, Brett PJ, Woods DE, (1998) The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 30: 1081-1100.
67. Ismail G, Razak N, Mohamed R, Embi N, Omar O, (1988) Resistance of Pseudomonas pseudomallei to normal human serum bactericidal action. Microbiol Immunol 32: 645-652.
68. Underhill DM, Ozinsky A, (2002) Phagocytosis of microbes: complexity in action. Annu Rev Immunol 20: 825-852.
69. Brown EJ, (1991) Complement receptors and phagocytosis. Curr Opin Immunol 3: 76-82.
70. Conlan JW, (1997) Critical role of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect Immun 65: 630-635.
71. Ceballos-Olvera I, Sahoo M, Miller MA, Del Barrio L, Re F (2011) Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1β is deleterious. PLoS Pathog 7.
72. Corbett D, Roberts IS, (2009) The role of microbial polysaccharides in host-pathogen interaction. F1000 Biol Rep 1: 1-3.
73. Roberts I, S., Saunders FK, Boulnois GJ, (1989) Bacterial capsules and interactions with complement and phagocytes. Biochem Soc Trans 17: 462-464.
74. Taylor CM, Roberts IS, (2005) Capsular polysaccharides and their role in virulence. Contrib Microbiol 12: 55-66.
75. Merino S, Tomas JM (2010) Bacterial capsules and evasion of immune responses. Encylopedia of Life Sciences. Hoboken, NJ: John Wiley and Sons, Ltd. 1-9.
76. Grossman N, Schmetz MA, Foulds J, Klima EN, Jimenez-Lucho VE, et al. (1987) Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol 169: 856-863.
77. Brett PJ, Burtnick MN, Woods DE, (2003) The wbiA locus is required for the 2-O-acetylation of lipopolysaccharides expressed by Burkholderia pseudomallei and Burkholderia thailandensis. FEMS Microbiol Lett 218: 323-328.
78. Ngugi SA, Ventura VV, Qazi O, Harding SV, Kitto GB, et al. (2010) Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine 28: 7551-7555.
79. Blom AM, Hallstrom T, Riesbeck K, (2009) Complement evasion strategies of pathogens-Acquisition of inhibitors and beyond. Mol Immunol 46: 2808-2817.
80. Balagopal A, MacFarlane AS, Mohapatra N, Soni S, Gunn JS, et al. (2006) Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages. Infect Immun 74: 5114-5125.
81. Schlesinger LS, Horwitz MA, (1994) A role for natural antibody in the pathogenesis of leprosy: antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes. Infect Immun 62: 280-289.
82. Yuste J, Botto M, Bottoms SE, Brown JS, (2007) Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog 3: 1208-1219.
83. Ng PM, Le Saux A, Lee CM, Tan NS, Lu J, et al. (2007) C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J 26: 3431-3440.
84. Harley VS, Dance DA, Tovey G, McCrossan MV, Drasar BS, (1998) An ultrastructural study of the phagocytosis of Burkholderia pseudomallei. Microbios 94: 35-45.
85. Kanthawong S, Bolscher JG, Veerman EC, van Marle J, de Soet HJ, et al. (2012) Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei. Int J Antimicrob Agents 39: 39-44.
86. Kanthawong S, Nazmi K, Wongratanacheewin S, Bolscher JG, Wuthiekanun V, et al. (2009) In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides. Int J Antimicrobial Agents 34: 309-314.
87. Sim SH, Liu Y, Tan J, Thong TW, Wang D, et al. (2011) Antimicrobial activity of cathelicidin peptides against Burkholderia pseudomallei, the causative agent of melioidosis. Int J Antimicrob Agents 38: 270-271.
88. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, et al. (2004) Neutrophil extracellular traps kill bacteria. Science 303: 1532-1535.
89. Standish AJ, Weiser JN, (2009) Human neutrophils kill Streptococcus pneumoniae via serine proteases. J Immunol 183: 2602-2609.
90. Nauseef WM, (2007) How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 219: 88-102.
91. Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, et al. (1981) Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 95: 293-301.
92. Chapman ALP, Hampton MB, Senthilmohan R, Winterbourn CC, Kettle AJ, (2002) Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of Staphylococcus aureus. J Biol Chem 277: 9757-9762.
93. Mayer-Scholl A, Hurwitz R, Brinkmann V, Schmid M, Jungblut P, et al. (2005) Human neutrophils kill Bacillus anthracis. PLoS Pathog 1.
94. Riyapa D, Buddhisa S, Korbsrisate S, Cuccui J, Wren BW, et al. (2012) Neutrophil extracellular traps exhibit antibacterial activity against Burkholderia pseudomallei and are influenced by bacterial and host factors. Infect Immun: In press.
95. Ermert D, Urban CF, Laube B, Goosmann C, Zychlinsky A, et al. (2009) Mouse neutrophil extracellular traps in microbial infections. J Innate Immun 1: 181-193.
96. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, et al. (2007) Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176: 231-241.
97. Dance DA (2005) Melioidosis and glanders as possible biological weapons. In: Fong, Alibek, editors. Bioterrorism and Infectious Agents. New York: Springer Science. 99-145.
98. Galyov EE, Brett PJ, Deshazer D, (2010) Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol 64: 495-517.
99. Mantovani A, Cassatella MA, Costantini C, Jaillon S, (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519-531.
100. Costantini C, Cassatella MA, (2011) The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity. J Leukoc Biol 89: 221-233.